Vireo Growth VREOF
OTC VREOF
$10.97 -0.01 (-0.09%)
At close: Aug 19, 2026 · 3:35 PM UTC

Vireo Growth (VREOF) Liabilities and Shareholders Equity (2020 - 2026)

Vireo Growth (VREOF) posted Liabilities and Shareholders Equity of $928.8 million for Q1 2026, up 13.66% sequentially from $817.2 million in Q4 2025, and up 235.25% YoY from $277.0 million in Q1 2025.

Vireo Growth (VREOF) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Vireo Growth has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $928.8 million in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 235.25% year-over-year to $928.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 billion (up 226.56% YoY) and the FY2025 annual result came in at $817.2 million, up 193.05% from the prior year.
  • Liabilities and Shareholders Equity rose to $928.8 million in Q1 2026 per VREOF's latest filing, from $817.2 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $928.8 million in Q1 2026 and troughed at $158.6 million in Q1 2023.
  • A 5-year average of $327.1 million and a median of $190.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
  • The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity fell 4.68% in 2022, then soared 250.19% in 2025.
  • Over 5 years, Liabilities and Shareholders Equity stood at $159.2 million in 2022, then increased by 15.15% to $183.3 million in 2023, then jumped by 52.16% to $278.9 million in 2024, then surged by 193.05% to $817.2 million in 2025, then grew by 13.66% to $928.8 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $928.8 million, $817.2 million, and $678.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 43.98 Bn 43.02 Bn - 43.71 Bn
2 Teva Pharmaceutical Industries 43.28 Bn 39.62 Bn 2.15 Bn 39.86 Bn
3 Zoetis 31.78 Bn 30.11 Bn 1.05 Bn 15.08 Bn
4 Takeda Pharmaceutical 28.71 Bn 22.91 Bn 5.10 Bn 98.27 Bn
5 United Therapeutics 22.25 Bn 19.59 Bn 683.80 Mn 7.22 Bn
6 Viatris 18.72 Bn 17.83 Bn 1.46 Bn 35.04 Bn
7 Neurocrine Biosciences 15.57 Bn 15.18 Bn 935.80 Mn 5.36 Bn
8 Elanco Animal Health 11.87 Bn 11.34 Bn 798.00 Mn 13.56 Bn
9 Dr Reddys Laboratories 10.14 Bn 9.97 Bn - 6.18 Bn
10 Vireo Growth 487.39 Mn 345.09 Mn 95.30 Mn 1.27 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 928.80 Mn
Dec 31, 2025 817.20 Mn
Sep 30, 2025 678.92 Mn
Jun 30, 2025 659.34 Mn
Mar 31, 2025 277.05 Mn
Dec 31, 2024 278.86 Mn
Sep 30, 2024 193.87 Mn
Jun 30, 2024 194.68 Mn
Mar 31, 2024 190.88 Mn
Dec 31, 2023 183.26 Mn
Sep 30, 2023 171.67 Mn
Jun 30, 2023 165.95 Mn
Mar 31, 2023 158.63 Mn
Dec 31, 2022 159.16 Mn
Sep 30, 2022 173.32 Mn
Jun 30, 2022 168.82 Mn
Mar 31, 2022 160.73 Mn
Dec 31, 2021 166.97 Mn
Sep 30, 2021 164.16 Mn
Jun 30, 2021 112.68 Mn